[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595888":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":55,"collaborators":20,"id":57,"slug":20,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":58,"sex":64,"minAge":65,"maxAge":20,"enrollmentInfo":66,"targetDuration":20,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":20,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"MDRT to oligoprogression","EXPERIMENTAL","Patients included in the study with a post prostatectomy local recurrence on the PSMA PET with up to 3 oligometastases will be treated preferably with SBRT to all oligometastatic lesions and to the local recurrence in prostate bed",[13],"Radiation: Metastasis directed radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Metastasis directed radiotherapy","According to guidelines, in the case of oligoprogression next line systemic treatment is recommended. This study investigates the potential delay of NEST and rPFS by MDRT.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Shafak Aluwini","CONTACT","+31625649975","s.al-uwini@umcg.nl",[28,41],{"facility":29,"status":30,"city":31,"state":20,"zip":20,"country":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"UMC Groningen","RECRUITING","Groningen","Netherlands",{"type":34,"coordinates":35},"Point",[36,37],6.56667,53.21917,{"lat":37,"lon":36},[40],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"facility":42,"status":43,"city":44,"state":20,"zip":20,"country":32,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Radboud Umc","NOT_YET_RECRUITING","Nijmegen",{"type":34,"coordinates":46},[47,48],5.85278,51.8425,{"lat":48,"lon":47},[51],{"name":52,"role":24,"phone":53,"phoneExt":20,"email":54},"Robert Jan Smeenk","+31 (024) 361 45 05","RobertJan.Smeenk@radboudumc.nl",{"type":56,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100595888",false,"NCT07038304","The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)","Oligometastatic Directed Radiotherapy for Patients With Castration Resistant Prostate Cancer","OLYMPIAN","Inclusion Criteria:\n\n* Adenocarcinoma of the prostate.\n* mCRPC setting, with testosterone level \\\u003C 50 ng\u002Fdl or 1.7 nmol\u002Fl.\n* Oligoprogressive disease diagnosed on PSMAscan; defined as the progression of pre-existing metastatic disease, and\u002For the appearance of new metastases and\u002For the appearance of a local relapse with a maximum of 3 lesions in total.\n* Patients currently treated with ADT, whether combined with another systemic treatment such as ARTA, chemotherapy.\n* For patients treated with chemotherapy, the course should be completed or stopped before start MORT - In case of treatment with ARTA, a minimal of 3 months response (PSA or clinical response).\n* WHO performance status 0-2.\n* Age \\> = 18 years old.\n* Patiënt should be presented at the multidisciplinary tumor board of the local hospital in which the therapy will be given.\n* Before patiënt registration, written informed consent must be given according to ICH\u002FGCO and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Serum testosterone level \\> 50 ng\u002Fml or \\> 1.7 nmol\u002Fl.\n* Presence of more than 3 progressive\u002Fnew metastatic lesions and\u002For local recurrence (which counts for 1 lesion).\n* Active malignancy other than prostate cancer that can potentially interfere with the interpretation of the trial, except non-melanoma skin cancer or non-invasive urothelial cell carcinoma.\n* Local recurrence in the prostate after previous radiotherapy\n* Previous treatments (RT, surgery) or comorbidities making new treatment with MDRT impossible.\n* Disorder precluding understanding of trial Information or informed consent or signing informed consent.\n* Evidence of PSMA-negative disease.","MALE","18 Years",{"count":67,"type":68},35,"ESTIMATED","INTERVENTIONAL",[71],"PHASE2","In patients with metastatic prostate cancer (PCa) who receive androgen deprivation therapy (ADT), the sensitivity to castration will eventually disappear due to the selection of castration-refractory clones. This will lead to the stage of metastatic castration-refractory prostate can-cer (mCRPC), which is incurable and results in a median overall survival of 2-3 years.\n\nTreatment options for patients with mCRPC include several systemic agents, such as andro-gen receptor-targeted agents (ARTA), chemotherapy (docetaxel, cabazitaxel) and bone-targeting agents (radium- 223). Clinical progression and, to a lesser extent, biochemical pro-gression traditionally imply a switch to the next line systemic treatment (NEST). Within patients with mCRPC, there is a subgroup showing oligo-progression, defined as the progression of up to 3 lesions, including both metastatic and\u002For local relapse. Oligoprogression reflects a heterogeneous treatment response, which, in turn, reflects the heterogeneity of the clonogenic cells that give rise to mCRPC. Retrospective studies suggest that metastasis-directed radiotherapy (MDRT) to these oligoprogressive lesions delayed the need for NEST. Recently, promising results were published on the use of MDRT in the oligopro-gressive mCRPC (omCRPC) setting, with a NEST-free survival (NEST-FS) of 21 months in well selected patients. Currently, in The Netherlands, patients with omCRPC are frequently referred and treated with MDRT, but a clear treatment protocol and inclusion\u002Fselection criteria are missing. Moreover, the exact benefit of MDRT in patients with omCRPC remains unclear, as prospective evi-dence for MDRT in omCRPC is lacking.",[74,75,76,77],"Prostate Cancer (Adenocarcinoma)","OligoProgressive Metastatic Disease","Castration Resistant Metastatic Prostate Cancer","Radiotherapy","2025-06-17",{"date":80,"type":81},"2025-06-26","ACTUAL",{"date":83,"type":81},"2025-01-03",{"date":85,"type":68},"2029-01-03",{"name":5,"class":6},2]